07:00 , Oct 7, 2013 |  BC Week In Review  |  Clinical News

IV Brinavess vernakalant: Clinical trial data

An open-label study in 150 patients with symptomatic, recent onset AF without structural heart disease or hemodynamic instability showed that patients treated with IV Brinavess achieved conversion to normal sinus rhythm in a median time...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Thermocool Navigation Catheters: Phase III data

The open-label, international Phase III RAFFT trial in 127 patients showed that first-line pulmonary vein isolation performed by radiofrequency catheter ablation met the primary endpoint of extending time to first recurrence of symptomatic or asymptomatic...
08:00 , Dec 12, 2011 |  BC Week In Review  |  Company News

KV Pharmaceutical drug delivery, generics news

KV reached a settlement with the Department of Justice and will pay $17 million over five years to resolve alleged False Claims Act violations by its former Ethex Corp. subsidiary. Specifically, DoJ alleged that Ethex...
07:00 , Oct 13, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Not applicable In vitro studies suggest propafenone analogs could help treat malaria. Synthesis and in vitro testing of a series of propafenone analogs...
07:00 , Mar 21, 2011 |  BioCentury  |  Politics, Policy & Law

Only the pricing is new

KV Pharmaceutical Co. last week drew congressional attention over the pricing of its newly approved Makena hydroxyprogesterone caproate to prevent preterm birth in women with a history of preterm delivery. The planned pricing - $1,500...
00:37 , Aug 31, 2010 |  BC Extra  |  Politics & Policy

ESC releases AF guidelines

The European Society of Cardiology (ESC) released guidelines for the management of atrial fibrillation . ESC said that patients with little or no underlying cardiovascular disease can be treated with "almost any antiarrhythmic drug that...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

NaviStar ThermoCool Irrigated Tip Catheter cardiovascular data

Data from a prospective, open-label trial in 167 patients who did not respond to at least 1 antiarrhythmic drug showed that catheter ablation with NaviStar met the primary endpoint of a significantly greater proportion of...
08:00 , Dec 11, 2008 |  BC Innovations  |  Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Tachycardia Troponin T type 2 (cardiac) (TNNT2) A mouse study suggests that blebbistatin may be useful for lowering Ca+ sensitivity in...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

Reliant, GlaxoSmithKline deal

GSK will acquire Reliant for $1.7 billion in cash. The acquisition gives GSK U.S. rights to Lovaza omega 3 acid ethyl esters, which is marketed for use as an adjunct to diet to treat hypertriglyceridemia....
08:00 , Dec 3, 2007 |  BioCentury  |  Finance

Ebb & Flow II

The $1.7 billion in cash that GlaxoSmithKline (LSE:GSK; GSK) paid for specialty pharma company Reliant is not providing a hefty return for some of the latter's long-term investors. Alkermes (ALKS), which owns 12.9% of Reliant,...